BriaCell Therapeutics Corp Stock

$0.70

6.57%

Nasdaq, Aug 22, 10:14 pm CET

ISIN

CA10778Y3023

Symbol

BCTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

BriaCell Therapeutics Corp Stock price

$0.70

-4.76 87.22% 5Y

Nasdaq, Closing price Fri, Aug 22 2025

+0.04 6.57%

ISIN

CA10778Y3023

Symbol

BCTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$12.1m

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

-40.6%

Return on Equity

201.1%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-24.3m | -

EBIT

$-24.4m | $-25.0m

Net Income

$-19.4m | -

Free Cash Flow

$-24.0m

EPS

$-5.2

FCF per Share

Short interest

0.2%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

BriaCell Therapeutics Corp Stock Analysis

Unlock Scores for Free

??

5 Analysts have issued a BriaCell Therapeutics Corp forecast:

4x Buy

80%

1x Hold

20%

More details on Analyst Estimates Including Price Targets

5 Analysts have issued a BriaCell Therapeutics Corp forecast:

Buy

80%

Hold

20%

Analyst Estimates with Stock Price Targets

Financial data from BriaCell Therapeutics Corp

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Apr '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	5.85 5.85	20% 20% -
- Research and Development Expense	19 19	34% 34% -
EBITDA	-24 -24	31% 31% -
- Depreciation and Amortization	0.15 0.15	650% 650% -
EBIT (Operating Income) EBIT	-24 -24	31% 31% -
Net Profit	-19 -19	241% 241% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BriaCell Therapeutics Corp Stock News

Neutral

GlobeNewsWire

●

4 days ago

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the “Consolidation”) of the Comp...

Neutral

GlobeNewsWire

●

12 days ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator...

Neutral

GlobeNewsWire

●

19 days ago

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the “Consolidation”) of the Comp...

More BriaCell Therapeutics Corp News

Company Profile

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Head office	Canada
CEO	William Williams
Employees	16
Founded	2006
Website	briacell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now